New Drug Combo Adds 4.5% More Weight Loss on Top of Tirzepatide in Trial
OrsoBio's oral TLC-6740 paired with tirzepatide boosted weight loss by an extra 4.5% in 24 weeks, with gains in insulin sensitivity and liver health.
Summary
OrsoBio has reported early clinical results showing that adding its oral drug TLC-6740 to tirzepatide — already one of the most effective weight-loss medications available — produced an additional 4.5% body weight reduction over 24 weeks compared to tirzepatide alone. The Phase 2a trial also found improvements in insulin sensitivity, liver health, and body composition, with no serious adverse events. The drug works by targeting mitochondria to increase how much energy the body burns. A related compound, TLC-1180, showed striking results in mice, including preserved muscle mass, better metabolic health across multiple organs, improved exercise capacity, and even reduced obesity-linked cognitive decline. TLC-1180 has now entered human safety trials.
Detailed Summary
Obesity treatment is entering a new phase, and OrsoBio's latest data suggests the ceiling on weight-loss drugs may be higher than previously thought. By combining a novel mitochondrial-targeting compound with tirzepatide — already one of the most potent GLP-1/GIP receptor agonists on the market — the company achieved meaningful additional fat loss, pointing toward a potential new class of metabolic medicine.
In a randomized, double-blind, placebo-controlled Phase 2a study lasting 24 weeks, participants taking once-daily oral TLC-6740 at 180 mg alongside weekly tirzepatide 5 mg lost an additional mean 4.5% of body weight compared to those on tirzepatide alone. Beyond weight loss, the combination improved insulin sensitivity, liver health markers, and body composition. Critically, adverse event rates were comparable between groups, and no Grade 3 or severe adverse events were reported, nor were there signs of dangerous systemic uncoupling — a key safety concern for mitochondrial protonophores.
Preclinical data on a next-generation compound, TLC-1180, further expands the story. In diet-induced obese mice, TLC-1180 increased energy expenditure and promoted fat-selective weight loss while preserving lean muscle mass. Whole-body insulin sensitivity reportedly improved by 140%, with benefits observed across the liver, muscle, heart, and adipose tissue. Notably, the compound also enhanced exercise capacity and reduced obesity-associated cognitive decline — a finding with significant longevity implications.
TLC-1180 has now entered a first-in-human Phase 1 safety trial, suggesting the company is moving quickly toward clinical translation. The underlying mechanism — mitochondrial protonophore activity — essentially encourages cells to burn more energy as heat, a concept sometimes called mitochondrial uncoupling.
Caveats are important here. Phase 2a trials are small and early-stage, preclinical mouse data rarely translates directly to humans, and the findings are being presented at a conference rather than published in a peer-reviewed journal. Independent replication and larger trials are needed before drawing firm conclusions.
Key Findings
- TLC-6740 added to tirzepatide produced an extra 4.5% mean weight loss over 24 weeks versus tirzepatide alone.
- The combination improved insulin sensitivity, liver health, and body composition with no serious adverse events.
- Preclinical TLC-1180 data showed 140% improvement in whole-body insulin sensitivity in obese mice.
- TLC-1180 preserved lean muscle mass while selectively reducing fat and improved exercise capacity in animals.
- TLC-1180 is now in a Phase 1 first-in-human safety study, marking a key clinical milestone.
Methodology
This is a news report summarizing conference presentations rather than a peer-reviewed publication, which limits independent verification. The clinical data comes from a small Phase 2a randomized controlled trial; preclinical findings are from company-reported animal studies. Source credibility is moderate — Longevity.Technology is a specialist outlet but relies on company-issued data.
Study Limitations
The 24-week Phase 2a trial is small and early-stage; effect sizes may not hold in larger, longer studies. Preclinical mouse data, including the 140% insulin sensitivity figure, rarely translates directly to humans and should be interpreted cautiously. Findings were presented at a conference and have not yet been published in a peer-reviewed journal with independent data verification.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.